Autolus Therapeutics (FRA:6A3A) Inventories, Work In Process: €5.41 Mil (As of Mar. 2026)


FRA:6A3A Autolus Therapeutics PLC FRA:6A3A
67 GF Score
Price €1.37
GF Value €15.79
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Autolus Therapeutics Inventories, Work In Process?

Autolus Therapeutics FRA:6A3A 67 Inventories, Work In Process is €5.41 Mil as of Mar. 2026. GuruFocus rates FRA:6A3A with a GF Score™ of 67/100 and a GF Value™ of €15.79 (Possible Value Trap). The stock has 7 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Autolus Therapeutics's work in process for the quarter that ended in Mar. 2026 was €5.41 Mil.

Autolus Therapeutics Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Autolus Therapeutics's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Autolus Therapeutics Inventories, Work In Process Chart

Autolus Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.02 3.10

Autolus Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.02 5.61 7.27 3.10 5.41
FRA:6A3A
67GF Score
Autolus Therapeutics PLC FRA:6A3A
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Autolus Therapeutics Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of €5.41 Mil mean?
Autolus Therapeutics (FRA:6A3A) has a Inventories, Work In Process of €5.41 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Autolus Therapeutics and its competitors.
Is Autolus Therapeutics' Inventories, Work In Process too high?
Autolus Therapeutics' current Inventories, Work In Process is €5.41 Mil. Overall, Autolus Therapeutics has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Autolus Therapeutics' Inventories, Work In Process compare to FBRX and SGMT?
Autolus Therapeutics' Inventories, Work In Process of €5.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Autolus Therapeutics and its competitors. Autolus Therapeutics's current Inventories, Work In Process is €5.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autolus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Autolus Therapeutics (FRA:6A3A) is currently considered Possible Value Trap. The stock's GF Value™ is €15.79, compared to a current price of €1.37 — trading 91.3% below its estimated fair value. The current Inventories, Work In Process is €5.41 Mil. Autolus Therapeutics' overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Autolus Therapeutics (FRA:6A3A), the current Inventories, Work In Process is €5.41 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Autolus Therapeutics (FRA:6A3A) Overvalued in 2026?

Based on GuruFocus' analysis, Autolus Therapeutics stock appears to be undervalued. The current stock price of €1.37 is trading 91.3% below its estimated GF Value™ of €15.79. GuruFocus considers Autolus Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:6A3A:

  • Inventories, Work In Process: €5.41 Mil
  • GF Value™: €15.79 vs. price of €1.37 (91.3% below fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the FRA:6A3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Autolus Therapeutics Business Description

Other Exchanges AUTL:USA6A3A:Germany
Address 191 Wood Lane, The MediaWorks, London, GBR, W12 7FP
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
67GF Score

Get the complete analysis for FRA:6A3A

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.37
Price
€15.79
GF Value